Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.

Quik JSE, Vollebergh MA, Retèl VP, van der Sluis K, Koemans WJ, van der Kaaij RT, Voets MM, Luyer MDP, van Hellemond IEG, Wijnhoven BPL, Mostert B, van Hillegersberg R, Mohammad NH, van Etten B, de Groot DJ, Helminen O, Hedberg J, Cashin PH, Harbjerg JL, Veenhof AAFA, Hartemink KJ, Kodach LL, van der Noort V, van Sandick JW, PERISCOPE II consortium

Open source

DOI
10.1016/s1470-2045(26)00144-0
Published
2026 Aug
Container
The Lancet. Oncology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00144-0,
  title = {Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.},
  author = {Quik JSE and Vollebergh MA and Retèl VP and van der Sluis K and Koemans WJ and van der Kaaij RT and Voets MM and Luyer MDP and van Hellemond IEG and Wijnhoven BPL and Mostert B and van Hillegersberg R and Mohammad NH and van Etten B and de Groot DJ and Helminen O and Hedberg J and Cashin PH and Harbjerg JL and Veenhof AAFA and Hartemink KJ and Kodach LL and van der Noort V and van Sandick JW and PERISCOPE II consortium},
  year = {2026},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(26)00144-0},
  url = {https://doi.org/10.1016/s1470-2045(26)00144-0}
}

RIS

TY  - JOUR
TI  - Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.
AU  - Quik JSE
AU  - Vollebergh MA
AU  - Retèl VP
AU  - van der Sluis K
AU  - Koemans WJ
AU  - van der Kaaij RT
AU  - Voets MM
AU  - Luyer MDP
AU  - van Hellemond IEG
AU  - Wijnhoven BPL
AU  - Mostert B
AU  - van Hillegersberg R
AU  - Mohammad NH
AU  - van Etten B
AU  - de Groot DJ
AU  - Helminen O
AU  - Hedberg J
AU  - Cashin PH
AU  - Harbjerg JL
AU  - Veenhof AAFA
AU  - Hartemink KJ
AU  - Kodach LL
AU  - van der Noort V
AU  - van Sandick JW
AU  - PERISCOPE II consortium
PY  - 2026
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(26)00144-0
UR  - https://doi.org/10.1016/s1470-2045(26)00144-0
ER  - 

APA

JSE, Q., MA, V., VP, R., K, V. D. S., WJ, K., RT, V. D. K., MM, V., MDP, L., IEG, V. H., BPL, W., B, M., R, V. H., NH, M., B, V. E., DJ, D. G., O, H., J, H., PH, C., JL, H., AAFA, V., KJ, H., LL, K., V, V. D. N., JW, V. S., & consortium, P. I. (2026). Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00144-0

Source records